Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director · Chief Executive Officer | March 16, 2022 | March 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date March 16, 2022 · Filed March 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.98 · Expires 2032-03-15 | Direct | 1,479,500 |
Reported balance
After 2022-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-16 · Grant · Acquired 1,479,500 · Balance 1,479,500 F1: 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months. |
Filing footnotes · ownership attribution and instrument terms
F1: 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2022 Filed Mar 18, 2022 16:07 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 1,479,500 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001209191-22-020004 · doc4.xml · derivative · entry 1 Homans Elizabeth · CIK 0001866220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,500 Underlying: Common Stock · 1,479,500 shares Expires 2032-03-15 F1 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 16:17 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 1,370,469 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0001209191-21-055899 · doc4.xml · derivative · entry 1 Homans Elizabeth · CIK 0001866220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370,469 Underlying: Common Stock · 1,370,469 shares Expires 2031-09-12 F1 · derivative.exercise_date: The shares vest in equal monthly installments over the forty-eight months following September 13, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.